Sirolimus Therapy and Dyslipidemia in Neonates and Infants: A Retrospective Cohort and Pharmacovigilance Analysis Authors: Akinobu Taniguchi, Basile Chrétien, Takashi Maeda, Kazuto Ueda, Ryosuke Miura, Ryuichi Tanaka, Toshihiko Suzuki, Yukako Muramatsu, Yoshiaki Sato, Kazuki Nishida Published: 2026 ABSTRACT ImportanceSirolimus is increasingly used for complex vascular and lymphatic anomalies in neonates and infants. While dyslipidemia is a known adverse effect in adults, the incidence, timing, and severity in this population remain poorly characterized.ObjectiveThe aim of this study was to evaluate the reporting odds and characteristics of sirolimus-associated dyslipidemia in neonates and infants compared with older populations.Design, Setting, and ParticipantsThis study combined a single-center retrospective cohort study and global pharmacovigilance analysis. The clinical cohort included neonates and infants treated with sirolimus at Nagoya University Hospital (October 2018–September 2025). The pharmacovigilance analysis utilized VigiBase (up to September 1, 2025) to perform age-stratified disproportionality analyses.Main Outcomes and MeasuresIn the clinical cohort, lipid profiles (total cholesterol, LDL-C, triglycerides) were assessed pre- and post-treatment. In VigiBase, adjusted reporting odds ratios (aRORs) for dyslipidemia and time-to-onset (TTO) were estimated across age groups, adjusting for sex, region, and concomitant medications.ResultsThe cohort included 10 patients (median age, 44.5 days). Post-initiation, 100% developed hypertriglyceridemia and 90% developed hypercholesterolemia. In VigiBase (17,802 sirolimus-related reports), the dyslipidemia reporting signal was highest in infants (28 days–23 months), with an aROR of 147.08 (95% CI 79.67–271.54), substantially exceeding that in adults aged 18–45 years (aROR 2.31; 95% CI 1.75–3.06). Among infant reports with available TTO data, median TTO was 11.0 days (IQR 5.5–15.8), compared with 29.5 days in adults.Conclusions and RelevanceNeonates and infants showed a markedly stronger dyslipidemia reporting signal than older age groups, and lipid abnormalities were common in the clinical cohort. These findings support baseline lipid assessment and early monitoring after sirolimus initiation in very young patients, including within the first two weeks of therapy. The pharmacovigilance findings should be interpreted as hypothesis generating.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40272-026-00754-5. Key Points Very young children receiving sirolimus often showed rises in cholesterol and triglyceride levels soon after treatment was started.In this study, these lipid changes were mostly laboratory findings and were not linked to documented serious clinical complications.Careful lipid monitoring early in treatment may help guide safer use of sirolimus in newborns and infants. Very young children receiving sirolimus often showed rises in cholesterol and triglyceride levels soon after treatment was started.In this study, these lipid changes were mostly laboratory findings and were not linked to documented serious clinical complications.Careful lipid monitoring early in treatment may help guide safer use of sirolimus in newborns and infants. Introduction Sirolimus (rapamycin), an mTOR inhibitor, has been increasingly used in neonates and infants since around 2015, particularly for mTOR-related disorders such as complex vascular and lymphatic anomalies—including lymphatic malformation, generalized lymphatic anomaly, and kaposiform hemangioendothelioma—in which aberrant activation of the mTOR pathway is implicated [1–4]. One of the major adverse effects of sirolimus therapy in adults is dyslipidemia, particularly hypercholesterolemia and hypertriglyceridemia [5–7]. Evidence from adult populations is relatively abundant, and the association between sirolimus therapy and lipid abnormalities has become clearer. Recent larger pediatric cohort studies have further expanded the clinical literature on sirolimus use in vascular and lymphatic anomalies [8, 9]. Similar findings have also been reported in children, where hypercholesterolemia and hypertriglyceridemia have been observed during treatment [10–15]. A systematic review of studies in which sirolimus was administered to pediatric patients reported dyslipidemia in 4.7% of cases [12]. In individual reports, a study of 67 children treated with sirolimus (median age 3.4 years [IQR 6.0]) found dyslipidemia in 19 patients (28.4%) [13]. Another study involving 14 pediatric patients aged 0–19 years (mean age 7 years) with vascular anomalies reported that dyslipidemia was the most common adverse effect of sirolimus therapy. Overall, 43% of patients developed lipid abnormalities, including hypercholesterolemia in 21% and hypertriglyceridemia in 21% [14]. In a study of 18 children under 2 years of age who received sirolimus for epilepsy associated with tuberous sclerosis complex, hyperlipidemia was reported in 88.89% of cases [15]. Although evidence on sirolimus use in the first year of life has begun to accumulate, data specifically addressing sirolimus-associated dyslipidemia in neonates and infants remain limited [16]. Case reports have described neonates with giant lymphatic malformations or large arteriovenous malformations who developed marked hypertriglyceridemia and hypercholesterolemia shortly after initiation of sirolimus therapy [1, 2], suggesting that lipid abnormalities may occur rapidly in this age group. In neonates and infants, age-related hepatic immaturity, limited adipose tissue and enzyme activity, nutritional status including breast milk or formula feeding, and differences in metabolic rate may significantly influence both drug and lipid metabolism [17]. These factors may result in pharmacokinetic and pharmacodynamic profiles that differ from those of adults and potentially lead to age-specific adverse effects. The clinical implications of dyslipidemia in this age group extend beyond mere laboratory abnormalities. Unlike adults, neonates and infants are in a critical phase of neurodevelopment and somatic growth, processes that are heavily dependent on adequate lipid intake [18, 19]. The development of severe hypertriglyceridemia often necessitates the restriction of lipid emulsions or fortified feeds, thereby risking growth failure and essential fatty acid deficiency [20, 21]. Furthermore, severe elevations in triglycerides pose a direct risk of acute pancreatitis and hepatic steatosis, complications that are particularly challenging to diagnose and manage in non-verbal infants [22, 23]. Consequently, understanding the specific timing and magnitude of this risk is essential for safe clinical management. However, clinical data directly addressing the timing, magnitude, and age-specific susceptibility of sirolimus-associated dyslipidemia in neonates and infants compared with older populations remain limited. The World Health Organization (WHO) maintains VigiBase, the international pharmacovigilance database, which contains more than 30 million spontaneous adverse event reports from over 170 countries. Analyses of VigiBase have demonstrated its utility in detecting pediatric-specific adverse drug reactions and characterizing age-related safety profiles [24–26]. This allows potential assessment of age-specific lipid abnormalities reporting associated with sirolimus. In this study, we evaluated lipid profile changes in neonates and infants treated with sirolimus in our neonatal intensive care unit (NICU). Additionally, we analyzed VigiBase reports to compare sirolimus-associated dyslipidemia across neonates/infants, older children, and adults. These analyses aim to identify potential age-specific reporting patterns and inform evidence-based strategies for monitoring and managing lipid abnormalities in this vulnerable population. Methods Retrospective Cohort Study Design and Participants We retrospectively reviewed the medical records of neonates and infants admitted to the NICU of Nagoya University Hospital who received sirolimus therapy between October 2018 and September 2025. Data collected included the indication for sirolimus, the age in days at treatment initiation, laboratory lipid profiles before and after initiation, and the timing of dyslipidemia onset. Given the continuous nutritional requirements of this population, lipid samples were obtained in a non-fasting state. None of the patients were receiving intravenous lipid emulsions at the time of lipid measurement after sirolimus initiation. The exact timing of blood sampling relative to enteral feeding was not systematically recorded and could not be retrospectively determined. Detailed nutritional and treatment-context variables—including type of enteral feeding (breast milk vs formula, including medium-chain triglyceride [MCT] formula use), caloric intake changes, and concurrent medications potentially affecting lipid metabolism or sirolimus exposure—were not systematically documented in the medical records and therefore could not be retrospectively standardized for analysis. Sirolimus therapy was initiated at a dose of 0.02 mg/kg, and the dosage was subsequently adjusted based on trough levels to maintain a target concentration of 5–15 ng/mL. Definition of Dyslipidemia The definitions of dyslipidemia were based on previously published pediatric reference values [27, 28] and were used in this study as pragmatic classification thresholds rather than as diagnostic cutoffs specifically validated for non-fasting NICU neonates and infants, as follows:Total cholesterol (TC): normal < 170 mg/dL; borderline 170–199 mg/dL; high ≥ 200 mg/dLLow-density lipoprotein cholesterol (LDL-C): normal < 110 mg/dL; borderline 110–129 mg/dL; high ≥ 130 mg/dLTriglycerides (TG): normal < 75 mg/dL; borderline 75–99 mg/dL; high ≥ 100 mg/dL Total cholesterol (TC): normal < 170 mg/dL; borderline 170–199 mg/dL; high ≥ 200 mg/dL Total cholesterol (TC): normal < 170 mg/dL; borderline 170–199 mg/dL; high ≥ 200 mg/dL Low-density lipoprotein cholesterol (LDL-C): normal < 110 mg/dL; borderline 110–129 mg/dL; high ≥ 130 mg/dL Low-density lipoprotein cholesterol (LDL-C): normal < 110 mg/dL; borderline 110–129 mg/dL; high ≥ 130 mg/dL Triglycerides (TG): normal < 75 mg/dL; borderline 75–99 mg/dL; high ≥ 100 mg/dL Triglycerides (TG): normal < 75 mg/dL; borderline 75–99 mg/dL; high ≥ 100 mg/dL Ethics The study was conducted in accordance with the tenets of the 1964 Declaration of Helsinki and its later amendments and the ethical guidelines of Japan. An opt-out opportunity for parents to refuse participation in this study was offered on the website of Nagoya University Hospital. This was deemed sufficient consent by the relevant ethics committee as this was a retrospective study using anonymized existing medical information. This study was approved by the Ethics Committee of Nagoya University Hospital (no. 2025-0285, approved on September 26, 2025). Pharmacovigilance Analysis We performed a retrospective pharmacovigilance study using a case-level extract of VigiBase (the WHO global database of individual case safety reports). Analyses used the VigiBase extract dated 1 September 2025 and MedDRA version 28.1 for adverse event coding. All outputs from the VigiBase component of the study were exported to the project output folder for reproducibility. Case Selection and Outcome Definition We retrieved all reports in which sirolimus was recorded as a suspected or interacting drug. Dyslipidemia events were defined using the standardized MedDRA grouping for dyslipidemia (the Dyslipidaemia SMQ), restricted to active preferred terms. This approach ensures the capture of diverse preferred terms (e.g., "Hypertriglyceridaemia," "Blood cholesterol increased," "Lipids increased") to maximize sensitivity. Reports with missing or implausible demographics and suspected duplicate reports were excluded prior to analysis. Age Categorization To explore developmental differences in reporting, reports were categorized into eight age strata: 0–27 days, 28 days–23 months, 2–11 years, 12–17 years, 18–45 years, 45–64 years, 65–74 years, and ≥ 75 years. All disproportionality and regression analyses were performed separately within each age stratum. Accordingly, no within-model age-category reference group was specified. The 18–45 years stratum was retained only as an adult comparator for presentation and interpretation across age groups. Drug Exposure and Covariates Sirolimus exposure was identified by mapping drug names to internal drug identifiers. We predefined and extracted several drug classes for adjustment based on ATC groupings: corticosteroids (ATC prefix H02), calcineurin inhibitors (L04AD), other mTOR/kinase inhibitors (L01EG), and lipid-modifying agents (C10). To avoid misclassification, sirolimus itself was excluded from the “other mTOR/kinase inhibitors” set. These medication groups were included as binary co-exposure covariates to reduce confounding by concomitant therapies known to influence lipid metabolism. Analytical Approach For each age stratum, we first computed descriptive statistics, that is, the number and proportion of dyslipidemia reports among all sirolimus-related reports. We then performed age-stratified disproportionality analyses. For each age stratum, we first calculated the crude reporting odds ratio (ROR) using a standard 2 × 2 case/non-case contingency table. We then fitted separate multivariable logistic regression models within each age stratum, with reporting of a dyslipidemia event (Yes/No) as the dependent variable and sirolimus exposure (Yes/No) as the primary independent variable. Reports involving all other drugs in the database served as the exposure reference. The models adjusted for sex, geographic region (with the Americas as the reference), and the following concomitant medication classes, treated as binary variables (reported/not reported): corticosteroids (ATC H02), calcineurin inhibitors (ATC L04AD), other mTOR/kinase inhibitors excluding sirolimus (ATC L01EG), and lipid-modifying agents (ATC C10). Adjusted model estimates were reported as adjusted reporting odds ratios (aRORs) with 95% confidence intervals. Because the analyses were stratified by age, age itself was not included as a covariate in these models. All statistical analyses were performed using R 4.5.1. Time-to-Onset and Dechallenge When available, time from drug initiation to onset of dyslipidemia (TTO) was extracted and summarized overall and within each age group. We also examined reported dechallenge (improvement after sirolimus withdrawal) information as supportive indicators of drug–event temporal association. TTO and dechallenge summaries were produced both overall and stratified by age group to allow comparison of temporal and causality indicators across developmental stages. Ethics and Data Governance All analyses used de-identified VigiBase data accessed under the applicable WHO/Uppsala Monitoring Centre data-use agreements. Because only anonymized secondary data were analyzed, individual informed consent and additional institutional review were not required. Results Retrospective Cohort Patient characteristics are summarized in Table 1. During the study period, sirolimus was administered to ten patients. Six cases were preterm infants. The indications were lymphatic malformation in four cases, generalized lymphatic anomaly in four cases, hemangioma in one case, and hemimegalencephaly in one case. The median age at initiation of sirolimus was 44.5 days (IQR 5.25–68.5). Table 1Patient characteristics of the retrospective cohortn = 10Females/males6/4Gestational age (weeks)a34 (32–37)Birth weight (g)a3195 (2806–3234)Preterm infant6Age at initiation of sirolimus (days)a44.5 (5.25–68.5)Lymphatic malformation4Generalized lymphatic anomaly4Hemangioma1Hemimegalencephaly1aMedian (IQR) Table 1Patient characteristics of the retrospective cohortn = 10Females/males6/4Gestational age (weeks)a34 (32–37)Birth weight (g)a3195 (2806–3234)Preterm infant6Age at initiation of sirolimus (days)a44.5 (5.25–68.5)Lymphatic malformation4Generalized lymphatic anomaly4Hemangioma1Hemimegalencephaly1aMedian (IQR) Patient characteristics of the retrospective cohort aMedian (IQR) Baseline lipid profiles within one week before treatment were available in eight out of ten patients. In the remaining two cases, baseline testing was not performed prior to sirolimus initiation at the discretion of the treating physician and was not associated with disease severity or clinical instability. Both patients were clinically stable at treatment initiation. Median (IQR) values were as follows: TC 105 mg/dL (100–119), LDL-C 45.5 mg/dL (32–54), and TG 91 mg/dL (48–98). Post-treatment lipid profiles were available in all ten patients. Patient-specific peak post-treatment values were TC 216 mg/dL (IQR 207–221), LDL-C 134.5 mg/dL (IQR 115–152), and TG 262 mg/dL (IQR 237–323). At baseline, eight out of eight patients had normal TC levels. After sirolimus initiation, one out of ten patients were borderline and nine were classified as high. LDL-C was normal in all eight patients at baseline; after treatment, two of ten remained normal, two were borderline, and six were high. For TG, three of eight were normal, three borderline, and two high at baseline, whereas after treatment all ten patients were classified as high. The timing at which laboratory values first reached the ‘high’ range differed across lipid fractions, occurring earliest for TC (median 14 days, IQR 8–37) and later for LDL-C (67 days, IQR 39–237) and TG (104 days, IQR 43–302). The median time to peak lipid levels after sirolimus initiation was 129.5 days (IQR 38.75–276) for TC, 178.5 days (IQR 61.75–309) for LDL-C, and 172.5 days (IQR 119.5–250.5) for TG. The individual longitudinal trajectories of TC, LDL-C, and TG during sirolimus therapy are shown in Fig. 1, which provides a patient-level overview of the temporal course of lipid abnormalities. Overall, these findings indicate fraction-specific temporal trajectories, with earlier threshold exceedance for TC and later elevation of LDL-C and TG.Fig. 1Individual longitudinal trajectories of lipid levels during sirolimus therapy. A, C, E Patients with available baseline (pre-treatment) lipid measurements; B, D, F patients without baseline measurements. Panels show A, B total cholesterol (TC), C, D low-density lipoprotein cholesterol (LDL-C), and E, F triglycerides (TG) measured over time during sirolimus treatment. The triangle (▲) indicates the initiation of sirolimus therapy. Horizontal dashed lines represent the predefined thresholds for elevated lipid levels (TC ≥ 200 mg/dL, LDL-C ≥ 130 mg/dL, TG ≥ 100 mg/dL) Individual longitudinal trajectories of lipid levels during sirolimus therapy. A, C, E Patients with available baseline (pre-treatment) lipid measurements; B, D, F patients without baseline measurements. Panels show A, B total cholesterol (TC), C, D low-density lipoprotein cholesterol (LDL-C), and E, F triglycerides (TG) measured over time during sirolimus treatment. The triangle (▲) indicates the initiation of sirolimus therapy. Horizontal dashed lines represent the predefined thresholds for elevated lipid levels (TC ≥ 200 mg/dL, LDL-C ≥ 130 mg/dL, TG ≥ 100 mg/dL) For completeness, we provide additional clinical details for the two patients without baseline lipid measurements. In one patient without baseline measurements (blue line in Fig. 1B, D, F), sirolimus was administered for a lymphatic malformation. A declining trend in TC and LDL-C levels was observed over time. This decrease temporally coincided with a sirolimus dose reduction implemented on day 42 due to an intercurrent infection; the dosage was reduced by half and subsequently restored to the original level on day 60. In another patient without baseline measurements (green line in Fig. 1B, D, F), sirolimus was administered for a cervical and thoracic lymphatic malformation. The clinical course was uneventful, and the initial dosage was maintained without adjustment until treatment completion. According to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 [29], Grade 2 TG elevations (> 300 mg/dL) were observed in four of ten patients, and Grade 3 hypertriglyceridemia (> 500 mg/dL) in one of ten; thus, five of ten patients reached Grade ≥ 2 TG elevation. Grade 2 TC elevation (> 300 mg/dL) was observed in 1 of 10 patients. No Grade 4 or 5 events were recorded. Because only a limited number of patients reached CTCAE Grade 2 or higher thresholds, and only one patient reached Grade 3, a formal summary of time to clinically meaningful or severe thresholds was not considered informative. No clinically apparent pancreatitis or other clinically significant symptoms attributable to dyslipidemia were documented in the medical records. Sirolimus dose reduction was undertaken at the discretion of the treating physician in some cases, but no temporary interruption or permanent discontinuation due to lipid abnormalities was documented. Specific dietary modifications in response to dyslipidemia were not systematically documented in the retrospective chart review. Among patients with follow-up laboratory data after dose reduction or after completion of sirolimus therapy (n = 5), lipid abnormalities improved in all cases. Sirolimus dose adjustment in these patients was individualized at the discretion of the treating physician rather than according to a predefined protocol, and detailed quantitative adjustment schedules were not consistently documented for retrospective summary. However, because laboratory assessments were performed at clinically determined rather than predefined intervals, the exact time to lipid normalization could not be reliably established.Fig. 2Age-stratified adjusted reporting odds ratios (aRORs) for dyslipidemia associated with sirolimus exposure in VigiBase. Points and horizontal lines represent aRORs and 95% confidence intervals derived from separate multivariable logistic regression models fitted within each age stratum. The dependent variable was reporting of dyslipidemia (Yes/No) and the primary independent variable was sirolimus exposure (Yes/No), with reports involving all other drugs serving as the exposure reference. Models were adjusted for sex, geographic region, and predefined co-medication classes. The age stratum 18–45 years is displayed as an adult comparator for presentation only and was not used as a within-model age reference category Age-stratified adjusted reporting odds ratios (aRORs) for dyslipidemia associated with sirolimus exposure in VigiBase. Points and horizontal lines represent aRORs and 95% confidence intervals derived from separate multivariable logistic regression models fitted within each age stratum. The dependent variable was reporting of dyslipidemia (Yes/No) and the primary independent variable was sirolimus exposure (Yes/No), with reports involving all other drugs serving as the exposure reference. Models were adjusted for sex, geographic region, and predefined co-medication classes. The age stratum 18–45 years is displayed as an adult comparator for presentation only and was not used as a within-model age reference category Pharmacovigilance Analysis Study Population and Overview A total of 17,802 sirolimus-related reports were retrieved from VigiBase up to 1 September 2025, including 430 dyslipidemia reports. Overall, reports originated from all WHO regions, with the highest contributions from the Americas (12,201 reports) and European (4275) regions. The age distribution showed that sirolimus-related reports were most frequent in adults aged 18–64 years (n = 8392), but pediatric and neonatal cases were also represented (0–27 days, n = 48; 28 days–23 months, n = 248; 2–11 years, n = 872; 12–17 years, n = 596). An additional 129 sirolimus-related reports had missing age information and were therefore not included in the age-stratified analyses. Disproportionality Analyses In crude disproportionality analyses, dyslipidemia was disproportionately reported with sirolimus compared with all other drugs in the database across several age strata. In separate age-stratified multivariable logistic regression models, sirolimus exposure remained independently associated with reporting of dyslipidemia across age groups after adjustment for sex, geographic region, and predefined co-medication classes (Fig. 2). Table 2 presents both the crude RORs and the adjusted RORs (aRORs). Table 2Crude reporting odds ratios (RORs) and adjusted reporting odds ratios (aRORs) for dyslipidemia associated with sirolimus exposure, estimated separately within each age stratumAge categoryNCrude disproportionality analysesMultivariable logistic regression analysesbRORa95% CIaRORc95% CI0–27 days338.711.87–126.1920.153.72–109.3228 days–23 months19329.89202.98–536.16147.0879.66–271.542–11 years4263.846.49–87.5715.7710.64–23.3812–17 years1613.258.05–21.824.892.85–8.3918–45 years609.217.13–11.902.311.75–3.0645–64 years1297.075.94–8.433.172.63–3.8165–74 years274.543.10–6.642.351.60–3.47≥ 75 years56.052.50–14.603.391.39–8.25NAd129aROR: crude reporting odds ratio from an age-stratified 2×2 case/non-case disproportionality analysisbAdjusted estimates were derived from separate multivariable logistic regression models fitted within each age stratum, with dyslipidemia reporting (Yes/No) as the dependent variable and sirolimus exposure (Yes/No) as the primary independent variable; reports involving all other drugs in the database served as the exposure reference; models were adjusted for sex, geographic region, and predefined co-medication classescaROR: adjusted reporting odds ratiodNA indicates reports with missing age information. These reports are shown for descriptive completeness only and were not included in the age-stratified ROR/aROR analyses Table 2Crude reporting odds ratios (RORs) and adjusted reporting odds ratios (aRORs) for dyslipidemia associated with sirolimus exposure, estimated separately within each age stratumAge categoryNCrude disproportionality analysesMultivariable logistic regression analysesbRORa95% CIaRORc95% CI0–27 days338.711.87–126.1920.153.72–109.3228 days–23 months19329.89202.98–536.16147.0879.66–271.542–11 years4263.846.49–87.5715.7710.64–23.3812–17 years1613.258.05–21.824.892.85–8.3918–45 years609.217.13–11.902.311.75–3.0645–64 years1297.075.94–8.433.172.63–3.8165–74 years274.543.10–6.642.351.60–3.47≥ 75 years56.052.50–14.603.391.39–8.25NAd129aROR: crude reporting odds ratio from an age-stratified 2×2 case/non-case disproportionality analysisbAdjusted estimates were derived from separate multivariable logistic regression models fitted within each age stratum, with dyslipidemia reporting (Yes/No) as the dependent variable and sirolimus exposure (Yes/No) as the primary independent variable; reports involving all other drugs in the database served as the exposure reference; models were adjusted for sex, geographic region, and predefined co-medication classescaROR: adjusted reporting odds ratiodNA indicates reports with missing age information. These reports are shown for descriptive completeness only and were not included in the age-stratified ROR/aROR analyses Crude reporting odds ratios (RORs) and adjusted reporting odds ratios (aRORs) for dyslipidemia associated with sirolimus exposure, estimated separately within each age stratum aROR: crude reporting odds ratio from an age-stratified 2×2 case/non-case disproportionality analysis bAdjusted estimates were derived from separate multivariable logistic regression models fitted within each age stratum, with dyslipidemia reporting (Yes/No) as the dependent variable and sirolimus exposure (Yes/No) as the primary independent variable; reports involving all other drugs in the database served as the exposure reference; models were adjusted for sex, geographic region, and predefined co-medication classes caROR: adjusted reporting odds ratio dNA indicates reports with missing age information. These reports are shown for descriptive completeness only and were not included in the age-stratified ROR/aROR analyses Time to Onset of Dyslipidemia Time-to-onset (TTO) information was available for 70 reports (Table 3). Overall, the median TTO was 34 days (IQR 10.5–87.2; range 0–1940 days). Table 3Time to onset of sirolimus associated dyslipidaemia, by age groupAge categorynMedian (IQR) [range], days0–27 days028 days–23 months411.0 (5.5–15.8) [1.0–18.0]2–11 years968.0 (10.0–76.0) [6.0–1316.0]12–17 years316.0 (8.0–110.5) [0.0–205.0]18–45 years1629.5 (16.5–62.2) [0.0–1940.0]45–64 years2565.0 (13.0–88.0) [0.0–1185.0]65–74 years927.0 (7.0–59.0) [5.0–165.0]≥ 75 years0Overall7034.0 (10.5–87.2) [0.0–1940.0] Table 3Time to onset of sirolimus associated dyslipidaemia, by age groupAge categorynMedian (IQR) [range], days0–27 days028 days–23 months411.0 (5.5–15.8) [1.0–18.0]2–11 years968.0 (10.0–76.0) [6.0–1316.0]12–17 years316.0 (8.0–110.5) [0.0–205.0]18–45 years1629.5 (16.5–62.2) [0.0–1940.0]45–64 years2565.0 (13.0–88.0) [0.0–1185.0]65–74 years927.0 (7.0–59.0) [5.0–165.0]≥ 75 years0Overall7034.0 (10.5–87.2) [0.0–1940.0] Time to onset of sirolimus associated dyslipidaemia, by age group In infants aged 28 days–23 months, the median reported TTO was 11 days (IQR 5.5–15.8), although this estimate was based on only four reports. Among older children (2–11 years), the median reported TTO was 68 days (IQR 10–76), and in adolescents (12–17 years) it was 16 days (IQR 8–110.5). In adults, median reported TTO ranged from 29.5 days (IQR 16.5–62.2) in the group aged 18–45 years to 65 days (IQR 13–88) in those aged 45–64 years. No valid TTO data were reported for neonates (0–27 days) or the ≥ 75-years category. Dechallenge Findings Information on positive dechallenge (improvement after drug withdrawal) was available in 61 reports (Table 4). Positive dechallenge was most frequently observed in adults aged 45–64 years (n = 16) and in both children aged 2–11 years and adults aged 18–45 years (n = 11 each). Among infants aged 28 days to 23 months, three positive dechallenge cases were reported, and one was observed in a neonate. Table 4Reports with positive dechallenge (improvement after drug withdrawal) by age categoryAge categoryPositive dechallenge (n)0–27 days128 days–23 months32–11 years1112–17 years318–45 years1145–64 years1665–74 years3≥ 75 years0Overall61 Table 4Reports with positive dechallenge (improvement after drug withdrawal) by age categoryAge categoryPositive dechallenge (n)0–27 days128 days–23 months32–11 years1112–17 years318–45 years1145–64 years1665–74 years3≥ 75 years0Overall61 Reports with positive dechallenge (improvement after drug withdrawal) by age category Discussion This study provides a dyslipidemia-focused assessment of sirolimus use in neonates and infants by integrating a clinical cohort with age-stratified pharmacovigilance data. In our clinical cohort, lipid changes followed fraction-specific trajectories: TC reached the predefined high range earlier, whereas LDL-C and TG exceeded thresholds later and all three fractions peaked after longer follow-up. Mirroring this, our global pharmacovigilance analysis revealed that infants aged 28 days to 23 months exhibited the highest aROR for dyslipidemia among all age groups. In parallel, the VigiBase time-to-onset analysis showed a short reported TTO in infants (median 11 days), but this estimate was based on only four infant reports and reflects the onset of composite dyslipidemia reports rather than fraction-specific laboratory changes. Taken together, these findings support early lipid monitoring after sirolimus initiation while indicating that the temporal pattern differs across lipid fractions. Although previous studies have identified hyperlipidemia as a common adverse effect of sirolimus in pediatrics, the reported frequency has varied widely, ranging from 4.7% to over 80%, likely due to heterogeneous age groups [10–15]. Recent pediatric cohort studies and an infant-focused systematic review have further expanded the literature on sirolimus use in vascular anomalies [8, 9, 16]. However, in most of this literature, dyslipidemia has been reported as one adverse event among many rather than examined as a primary age-stratified outcome. Our findings align most closely with studies focusing on younger cohorts. For instance, Śmiałek et al. reported hyperlipidemia in 88.9% of children under 2 years treated for tuberous sclerosis [15]. Our study extends this literature by specifically characterizing lipid abnormalities and their temporal pattern in neonates and infants and by comparing reporting associations across age groups. The stark difference in aROR between infants and older children highlights a potential developmental window of vulnerability that closes as metabolic pathways mature. The high incidence of hyperlipidemia in this population creates a complex clinical dilemma that extends beyond simple drug toxicity. The management of severe hypertriglyceridemia typically involves dietary fat restriction. However, in neonates and infants, lipids provide approximately 50% of total caloric intake and are indispensable for myelination and somatic growth [21]. Clinicians are thus forced into a precarious trade-off: continuing a life-saving drug (sirolimus) at the cost of metabolic toxicity, or restricting lipids to treat the toxicity at the cost of growth failure. Because TC crossed the predefined high threshold early in our cohort, whereas LDL-C and TG tended to rise later, clinically relevant lipid abnormalities may emerge early after treatment initiation but continue to evolve over time. These fraction-specific trajectories support early post-initiation monitoring, followed by continued surveillance beyond the first weeks of therapy. Our data imply that clinicians must adopt a ‘proactive management’ strategy: anticipating the spike, monitoring lipids weekly during induction, and considering early, modest dose adjustments or the use of MCT formulas to maintain caloric intake while mitigating triglyceride accumulation. The biological plausibility of this age-specific susceptibility likely involves both mTOR-pathway regulation of lipid homeostasis and the developmental metabolic context of early life. mTORC1 is a central regulator of lipid metabolism through the lipin 1/SREBP axis, and pharmacologic inhibition by sirolimus perturbs this regulatory network [30]. Clinical and kinetic studies suggest that sirolimus-associated dyslipidemia is driven less by a simple increase in de novo lipogenesis than by impaired clearance of apoB-containing lipoproteins, including reduced fractional catabolism of VLDL-apoB100 and LDL-apoB100 and increased ApoC-III levels [31, 32]. Because ApoC-III inhibits lipoprotein lipase-mediated triglyceride hydrolysis, this shift can promote accumulation of triglyceride-rich lipoproteins [33]. Sirolimus has also been associated with increased PCSK9 expression, which may further impair LDL receptor-mediated clearance [34]. In neonates and infants, who depend on high lipid flux to support growth and neurodevelopment, even a modest drug-induced reduction in lipoprotein clearance may translate into earlier and more marked lipid abnormalities. Although these pathways were not directly measured in our study, they provide a biologically plausible framework for the marked and early dyslipidemia signal observed in this age group [30, 33, 34]. A major strength of this study is the combined use of a real-world clinical cohort and a large international database. Although the clinical cohort was small, the global pharmacovigilance analysis provided complementary large-scale data that helped contextualize the cohort findings. Conversely, clinical details that cannot be captured in VigiBase—such as the severity of dyslipidemia and the timing of its onset—were supplemented by the detailed information available from the cohort. This study is subject to several limitations that should be considered when interpreting the findings. First, in this study, lipid measurements were obtained in a non-fasting state due to the continuous feeding requirements of neonates and infants, so we were unable to assess the relationship between lipid abnormalities and feeding. Triglyceride levels in infants and young children have been reported to be influenced by feeding [35], and this may have affected some of the measurements. Accordingly, the proportion classified as abnormal in this cohort, particularly for TG, may have been overestimated by the use of non-fasting measurements and should be interpreted as a descriptive classification based on pediatric reference thresholds rather than as a definitive estimate of dyslipidemia prevalence. In contrast, total cholesterol and LDL-C are reported to be minimally affected by recent food intake [36], suggesting that the dyslipidemia observed in our cohort cannot be explained by feeding effects alone. Although none of the patients were receiving intravenous lipid emulsions at the time of post-sirolimus lipid measurement, detailed nutritional and treatment-context variables—including type of enteral feeding (breast milk vs formula, including MCT formula use), caloric intake changes, and concurrent medications potentially affecting lipid metabolism or sirolimus exposure—were not systematically documented. Therefore, residual confounding cannot be fully excluded, particularly for triglyceride levels, and attribution of elevated TG solely to sirolimus should be made cautiously. In addition, baseline lipid profiles were unavailable in two of the ten patients. Because these missing baseline measurements were attributable to physician discretion rather than documented clinical instability, substantial bias related to illness severity is unlikely; however, baseline prevalence may have been underestimated, and time-to-onset estimates in these two patients should be interpreted cautiously because pre-treatment lipid status could not be confirmed. Although sirolimus trough concentrations were measured in the clinical cohort, corresponding exposure data are not available in the VigiBase database. Because of the limited number of patients in the cohort and the absence of comparable exposure information in the pharmacovigilance dataset, a formal analysis of the relationship between sirolimus concentration and lipid abnormalities was not performed in the present study. Notably, most patients maintained trough concentrations within the target range of 5–15 ng/mL, as described in the Methods section. Next, the analysis relied on spontaneous reports from VigiBase, which are inherently affected by reporting bias and underreporting. The likelihood of submitting a report can vary across regions, healthcare settings, and reporter types, introducing systematic variability that may influence observed associations. Furthermore, the absence of denominator data means that disproportionality estimates and reporting odds ratios reflect reporting patterns rather than true incidence or risk, limiting the ability to quantify absolute risk. Although multivariable models adjusted for key co-medications and demographic factors, residual confounding from unmeasured variables such as baseline lipid levels, comorbidities, and treatment duration cannot be excluded. Data quality and completeness also pose challenges; missing or implausible demographic and clinical details led to case exclusions, and remaining reports may still contain inaccuracies. Time-to-onset and dechallenge information were inconsistently reported, reducing the strength of causal inference. The clinical context of sirolimus use adds complexity, as it is often prescribed in settings involving polypharmacy and severe underlying conditions such as transplantation or oncology. Specifically, the ‘Neonate’ (0–27 days) signal was lower than the ‘Infant’ signal; this may reflect the complexity of NICU care, where dyslipidemia might be attributed to total parenteral nutrition (TPN) or sepsis rather than the drug, leading to underreporting. Despite adjustment for major ATC drug classes, indication-related factors and other concomitant therapies may influence lipid metabolism and reporting patterns. Additionally, VigiBase aggregates data from diverse national pharmacovigilance systems with varying coding practices and thresholds for seriousness, which may affect comparability across regions and age groups. Furthermore, sirolimus dose intensity and treatment duration could not be reliably incorporated into the age-stratified multivariable logistic regression models used for the pharmacovigilance analysis. While recent evidence suggests that the incidence of sirolimus-associated adverse effects may vary with drug concentration [37], VigiBase reports often lack critical physiological data such as patient weight. In neonates and infants, where dosing is strictly weight-based, the absence of weight data precludes reliable categorization of dose intensity. Likewise, treatment start and stop dates were inconsistently reported, preventing reliable derivation of treatment duration as a covariate. Consequently, we cannot exclude the possibility that cumulative exposure or dose-dependent effects may have influenced the observed RORs. Finally, spontaneous reporting systems cannot establish causality. The observed associations should therefore be interpreted as hypothesis-generating signals that warrant confirmation in controlled studies with robust exposure and outcome ascertainment. Conclusion Our findings support the observation that sirolimus therapy in neonates and infants is disproportionately associated with reports of dyslipidemia. While sirolimus remains an important therapeutic option for serious mTOR-related conditions in early life, clinicians should recognize the heightened susceptibility to lipid abnormalities in this age group. Current monitoring protocols derived from older populations are likely inadequate. We recommend that lipid screening be performed at baseline and repeated within the first 7–14 days of therapy. Early recognition allows for timely intervention—whether through dose optimization or nutritional support—to ensure the safe and effective use of this critical therapy in vulnerable infants. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 186 KB) Supplementary file1 (PDF 186 KB)